EZH2 and mature T-cell and NK-cell non-Hodgkin lymphoma: Recently, results from a phase I trial on 28 patients with R/R PTCL (17 AITL, 11 PTCL-NOS) treated with selective EZH2 inhibitor SHR2554 demonstrated an ORR of 61%, median PFS of 11.1 months and 12-month OS of 92% [118].